Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENTA Enanta Pharmaceuticals	$7.89 -1.0%	$6.54	$4.09 ▼ $17.24	$168.66M	0.84	283,659 shs	78,004 shs
KPTI Karyopharm Therapeutics	$4.62 +0.2%	$4.97	$3.51 ▼ $16.95	$37.93M	0.24	76,706 shs	36,017 shs
NXTC NextCure	$0.44 +2.0%	$0.48	$0.22 ▼ $1.82	$12.22M	1.06	127,114 shs	86,057 shs
PTLA Portola Pharmaceuticals	$18.03	$18.03	$5.31 ▼ $31.73	$1.42B	2.32	3.17 million shs	N/A
RCKT Rocket Pharmaceuticals	$2.90 +0.6%	$4.50	$2.19 ▼ $26.98	$309.68M	0.67	2.22 million shs	1.75 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENTA Enanta Pharmaceuticals	0.00%	+5.20%	+9.43%	+66.81%	-39.95%
KPTI Karyopharm Therapeutics	0.00%	+5.24%	+8.45%	+19.69%	-62.81%
NXTC NextCure	0.00%	-2.89%	-11.81%	+12.02%	-72.17%
PTLA Portola Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
RCKT Rocket Pharmaceuticals	0.00%	+14.47%	+4.55%	-43.44%	-85.54%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ENTA Enanta Pharmaceuticals	4.0828 of 5 stars	3.4	2.0	0.0	4.7	2.4	2.5	0.0
KPTI Karyopharm Therapeutics	3.8397 of 5 stars	3.5	1.0	0.0	4.6	0.6	2.5	0.6
NXTC NextCure	4.129 of 5 stars	3.5	3.0	0.0	4.3	0.0	1.7	1.3
PTLA Portola Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	4.8828 of 5 stars	4.2	2.0	0.0	4.7	2.2	5.0	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ENTA Enanta Pharmaceuticals	2.80	Moderate Buy	$18.00	128.14% Upside
KPTI Karyopharm Therapeutics	3.00	Buy	$43.20	835.06% Upside
NXTC NextCure	3.00	Buy	$3.50	700.92% Upside
PTLA Portola Pharmaceuticals	0.00	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	2.41	Hold	$18.60	542.27% Upside

Current Analyst Ratings Breakdown

Latest KPTI, NXTC, PTLA, RCKT, and ENTA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/1/2025	NXTC NextCure	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00
6/17/2025	RCKT Rocket Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $5.00
6/3/2025	ENTA Enanta Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$23.00 ➝ $24.00
6/3/2025	RCKT Rocket Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$34.00 ➝ $11.00
5/30/2025	RCKT Rocket Pharmaceuticals	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ In-Line	$5.00
5/28/2025	RCKT Rocket Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/28/2025	RCKT Rocket Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral
5/28/2025	RCKT Rocket Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$32.00 ➝ $9.00
5/28/2025	RCKT Rocket Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $8.00
5/28/2025	RCKT Rocket Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$51.00 ➝ $19.00
5/28/2025	RCKT Rocket Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Sell

(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ENTA Enanta Pharmaceuticals	$67.64M	2.49	N/A	N/A	$6.08 per share	1.30
KPTI Karyopharm Therapeutics	$145.24M	0.27	N/A	N/A	($22.10) per share	-0.21
NXTC NextCure	N/A	N/A	N/A	N/A	$2.34 per share	N/A
PTLA Portola Pharmaceuticals	$116.64M	12.13	N/A	N/A	$1.67 per share	10.80
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	$5.08 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ENTA Enanta Pharmaceuticals	-$116.04M	-$4.54	N/A	N/A	N/A	-149.57%	-79.83%	-26.65%	8/4/2025 (Estimated)
KPTI Karyopharm Therapeutics	-$76.42M	-$13.26	N/A	N/A	N/A	-43.99%	N/A	-35.95%	8/5/2025 (Estimated)
NXTC NextCure	-$55.65M	-$1.76	N/A	N/A	N/A	N/A	-70.16%	-58.10%	7/30/2025 (Estimated)
PTLA Portola Pharmaceuticals	-$290.66M	-$4.06	N/A	N/A	N/A	-232.73%	-267.86%	-54.66%	N/A
RCKT Rocket Pharmaceuticals	-$258.75M	-$2.63	N/A	N/A	N/A	N/A	-64.92%	-56.13%	8/4/2025 (Estimated)

Latest KPTI, NXTC, PTLA, RCKT, and ENTA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.58	-$0.56	+$0.02	N/A	N/A	N/A
5/12/2025	Q2 2025	ENTA Enanta Pharmaceuticals	-$1.04	-$1.06	-$0.02	-$1.06	$15.96 million	$14.93 million
5/12/2025	Q1 2025	KPTI Karyopharm Therapeutics	-$4.21	-$2.77	+$1.44	-$2.77	$35.12 million	$30.02 million
5/5/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.59	-$0.56	+$0.03	-$0.56	$0.80 million	N/A
5/1/2025	Q1 2025	NXTC NextCure	-$0.40	-$0.39	+$0.01	-$0.39	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ENTA Enanta Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KPTI Karyopharm Therapeutics	N/A	N/A	N/A	N/A	N/A
NXTC NextCure	N/A	N/A	N/A	N/A	N/A
PTLA Portola Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ENTA Enanta Pharmaceuticals	N/A	5.29	5.29
KPTI Karyopharm Therapeutics	N/A	1.33	1.28
NXTC NextCure	N/A	10.26	10.26
PTLA Portola Pharmaceuticals	4.77	4.87	4.82
RCKT Rocket Pharmaceuticals	0.05	9.19	9.19

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ENTA Enanta Pharmaceuticals	94.99%
KPTI Karyopharm Therapeutics	66.44%
NXTC NextCure	42.65%
PTLA Portola Pharmaceuticals	98.68%
RCKT Rocket Pharmaceuticals	98.39%

Insider Ownership

Company	Insider Ownership
ENTA Enanta Pharmaceuticals	13.89%
KPTI Karyopharm Therapeutics	2.98%
NXTC NextCure	17.90%
PTLA Portola Pharmaceuticals	2.20%
RCKT Rocket Pharmaceuticals	24.76%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ENTA Enanta Pharmaceuticals	160	21.38 million	18.41 million	Optionable
KPTI Karyopharm Therapeutics	380	8.64 million	8.38 million	Optionable
NXTC NextCure	90	28.05 million	23.03 million	Optionable
PTLA Portola Pharmaceuticals	324	78.48 million	N/A	Optionable
RCKT Rocket Pharmaceuticals	240	106.79 million	80.35 million	Optionable

KPTI, NXTC, PTLA, RCKT, and ENTA Headlines

Recent News About These Companies

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals

July 6 at 8:20 AM | globenewswire.com

SonyLIV's Rocket Boys Continues To Clocks High Viewership

July 5 at 8:49 AM | deccanchronicle.comD

Rocket Report: Japan’s workhorse booster takes a bow; you can invest in SpaceX now

July 4 at 5:20 PM | arstechnica.comA

Avid Cider Company’s Rocket Cider Pops Off Again

July 4 at 5:20 PM | wweek.comW

US Air Force Suspends SpaceX Rocket Project on Pacific Atoll, Report Says

July 4 at 5:20 PM | usnews.com

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Rocket Pharmaceuticals, Inc. ...

July 4 at 12:34 PM | gurufocus.com

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RCKT

July 4 at 11:17 AM | globenewswire.com

Rocket Fires Back At 'Noise' of Redfin Acquisition Being 'Bad For Brokers'

July 3 at 7:18 PM | nationalmortgageprofessional.comN

Rocket Pharmaceuticals, Inc. (RCKT) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Morningstar

July 3 at 7:18 PM | morningstar.comM

Contact Levi & Korsinsky by August 11, 2025 Deadline to Join Class Action Against Rocket Pharmaceuticals, Inc. (RCKT)

July 3 at 4:33 PM | globenewswire.com

RCKT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

July 3 at 4:00 PM | globenewswire.com

RCKT INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit

July 3 at 2:15 PM | prnewswire.com

Rocket Pharmaceuticals, Inc. (RCKT) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

July 3 at 12:37 PM | prnewswire.com

Investors in Rocket Pharmaceuticals, Inc. ...

July 3 at 10:15 AM | gurufocus.com

Investors in Rocket Pharmaceuticals, Inc. Should Contact The Gross Law Firm Before August 11, 2025 to Discuss Your Rights - RCKT

July 3 at 9:00 AM | prnewswire.com

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals

July 3 at 8:01 AM | prnewswire.com

Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class Action Amid Protocol Change and FDA's Clinical Hold on Gene Therapy Trial â€“ Hagens Berman

July 2, 2025 | globenewswire.com

RCKT LAWSUIT ALERT: The Gross Law Firm Notifies Rocket Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

July 2, 2025 | globenewswire.com

RCKT Investors Have Opportunity to Lead Rocket Pharmaceuticals, Inc. Securities Fraud Lawsuit

July 2, 2025 | prnewswire.com

Rocket Pharmaceuticals, Inc. (RCKT) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

July 2, 2025 | prnewswire.com

Sovran Advisors LLC Purchases 172,324 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

June 29, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KPTI, NXTC, PTLA, RCKT, and ENTA Company Descriptions

Enanta Pharmaceuticals NASDAQ:ENTA

$7.89 -0.08 (-1.00%)

As of 07/3/2025 01:04 PM Eastern

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Karyopharm Therapeutics NASDAQ:KPTI

$4.62 +0.01 (+0.22%)

Closing price 07/3/2025 02:45 PM Eastern

Extended Trading

$4.49 -0.13 (-2.81%)

As of 07/3/2025 04:28 PM Eastern

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

NextCure NASDAQ:NXTC

$0.44 +0.01 (+2.03%)

As of 07/3/2025 03:52 PM Eastern

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

Portola Pharmaceuticals NASDAQ:PTLA

Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation in the United States. The company offers Andexxa, an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients hospitalized for an acute medical illness. It is also advancing cerdulatinib, a dual spleen tyrosine kinase and janus kinases inhibitor in development for the treatment of hematologic cancers. In addition, the company is developing PRT2761, a Syk inhibitor that has completed Phase II clinical trial for the treatment for allergic conjunctivitis. Portola Pharmaceuticals, Inc. has collaboration agreements with Bristol-Myers Squibb; Pfizer Inc.; Bayer Pharma, AG; Janssen Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Millennium Pharmaceuticals, Inc.; SRX Cardio; LLC; Ora; and Astellas Pharma Inc. The company was founded in 2003 and is headquartered in South San Francisco, California.

Rocket Pharmaceuticals NASDAQ:RCKT

$2.90 +0.02 (+0.56%)

Closing price 07/3/2025 03:49 PM Eastern

Extended Trading

$2.89 -0.01 (-0.21%)

As of 07/3/2025 04:55 PM Eastern

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time